表紙
市場調查報告書

支持AI的藥物輸送和臨床實驗:全球市場的分析與預測(2019∼2030年)

Global AI-Enabled Drug Discovery and Clinical Trials Market: Analysis and Forecast, 2019-2030

出版商 BIS Research Inc. 商品編碼 930639
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
支持AI的藥物輸送和臨床實驗:全球市場的分析與預測(2019∼2030年) Global AI-Enabled Drug Discovery and Clinical Trials Market: Analysis and Forecast, 2019-2030
出版日期: 2020年03月18日內容資訊: 英文 211 Pages
簡介

全球支持AI的藥物輸送和臨床實驗市場至2030年預計將達到42億4,000萬美元。該市場在2019∼2030年的年複合成長率預計將以24.88%大幅成長。受益於這些軟件解決方案,另一方面法律規章的不足和道德問題等也留下很大的課題。

本報告提供全球支持AI的藥物輸送和臨床實驗市場相關調查,市場趨勢,市場佔有率預測,競爭趨勢,各市場區隔趨勢,參與企業的簡介等相關資訊彙整。

第1章 產品定義

第2章 調查範圍

第3章 調查方法

第4章 產業分析

  • 產業結構
  • 價值分析
  • 相關法規和政府的配合措施

第5章 開發平台分析

第6章 競爭環境

  • 策略與發展
  • 經營模式分析
  • 競爭基準

第7章 市場趨勢

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會

第8章 支持AI的藥物輸送和臨床實驗市場

  • 假設與限制
  • 主要調查結果與機會評估

第9章 各零件市場

  • 概要
  • 解決方案
  • 服務

第10章 各用途市場

  • 概要
  • 資料凝集,分析
  • 臨床實驗
  • 藥物設計
  • 藥物特性化
  • 生物標記研究

第11章 各治療用途市場

  • 概要
  • 腫瘤
  • 心血管疾病
  • 神經系統疾病
  • 呼吸器官障礙
  • 代謝性疾病
  • 免疫系疾病
  • 感染疾病
  • 其他

第12章 各終端用戶市場

  • 概要
  • 生物醫藥品產業
  • CRO
  • 學術機構,研究中心

第13章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第14章 企業簡介

目錄
Product Code: BH206A

Global AI-Enabled Drug Discovery and Clinical Trials Market to Reach $4.24 Billion by 2030

Key Questions Answered in the Report:

  • How can AI integration in drug discovery and clinical trials decrease drug development expenditure?
  • How are pharmaceutical/biopharmaceutical companies assisting in market development?
  • How can regulatory bodies such as FDA accelerate the AI adoption within the drug discovery and development process?
  • What is the present status of AI adoption in the drug discovery and development processes globally?
  • Which companies are expected to emerge as the key players of the market?
  • How are the companies operating in the market generating revenue?
  • What are the key regulatory implications in developed and developing regions for AI-enabled drug discovery and clinical trials market?
  • How can the companies expand in non-English speaking regions?
  • Which therapeutic area (such as oncology and neurology) has the highest AI adoption rate in clinical trials?
  • Which region is anticipated to serve as an emerging market for drug discovery and clinical trial, respectively?
  • What is the state of AI adoption in the Middle East and Latin America?
  • What are the different methodologies followed by the companies in the market for drug development?

Global AI-Enabled Drug Discovery and Clinical Trials Market, Forecast, 2019-2030

The Global AI-Enabled Drug Discovery and Clinical Trials Market Report by BIS Research projects the market to grow at a significant CAGR of 24.88% during the forecast period from 2019 to 2030. The market has evolved dramatically with increasing drug development expenditure and growing synergistic activities.

Despite the benefits of these software solutions, the major challenges in the market are lack of regulations and ethical issues. Some of the major opportunities for the key vendors in the market could be investment opportunities in emerging economies such as India, China, and Brazil and the introduction of systems in different languages.

Expert Quote

"Biopharmaceutical companies are the major end users of the AI-enabled drug discovery and clinical trials market in terms of revenue share. The biopharmaceutical companies market share is expected to increase up to $2,692.8 million. However, the usage of the solutions is expected to increase in contract research organizations and academic & research centers in order to streamline the workflow of the facilities and improve the quality of care."

Scope of the Market Intelligence on Global AI-Enabled Drug Discovery and Clinical Trials Market

The purpose of this study is to gain a holistic view of the global AI-enabled drug discovery and clinical trials market in terms of various influencing factors such as regional adoption trends, component types, applications, therapeutic applications, and end users.

The scope of this report constitutes an in-depth study of the global AI -enabled drug discovery and clinical trials market, including a thorough analysis of the products in the market as well as their adoption spanning different geographical regions. The market has been chiefly segmented into component type, application, therapeutic application, end user, and region. The report provides the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

Market Segmentation

The Global AI -Enabled Drug Discovery and Clinical Trials Market can be segmented on the basis of component type, application, therapeutic application, end user, and region. As of 2018, AI- enabled solutions accounted for $207.5 million and is expected to reach a value of $3,385.0 million by the end of 2030. In terms of growth, the end users and academic institutes and research centers segment is expected to grow at the highest CAGR of 25.45% during the forecast period.

As of 2018, North America is the largest shareholder for the overall market and is expected to reach a value of $2,460.5 million by the end of 2030, growing with a CAGR of 24.47% during the forecast period. However, a higher growth rate can be expected from the Asia-Pacific region, considering its improving healthcare infrastructure, overburdened healthcare system, and focus of ASEAN countries to be recognized as a medical tourism destination.

Although the adoption rate of the AI-enabled solutions has been moderate, the potential that lies in them is immense. The integration AI-enabled solutions in the healthcare facility will not only enhance medical research but also help research organizations in cost containment. To make the entire drug discovery and development process more efficient, the AI -enabled solutions can be integrated across various stakeholders, namely biopharmaceutical companies, contract research organizations (CROs), academic institutes, and research centers.

Key Companies in the Global AI-Enabled Drug Discovery and Clinical Trials Market

Some of the major key players in the global AI-enabled drug discovery and clinical trials market include Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc., Benevolent AI, Berg, LLC, Berkeley Lights, Inc., BioAge Labs, Inc., Biovista, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason, and Concerto HealthAI.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Report

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Companies Profiled
  • 3.5 Assumptions and Limitations

4 Industry Analysis

  • 4.1 Industry Trends
    • 4.1.1 Incorporation Trends
  • 4.2 Value Analysis
    • 4.2.1 Drug Discovery
    • 4.2.2 Clinical Trials
  • 4.3 Regulatory Framework and Government Initiatives
    • 4.3.1 Regulatory Framework in North America
    • 4.3.2 Regulatory Framework in Europe
    • 4.3.3 Government Initiatives
      • 4.3.3.1 Government Initiatives in North America
      • 4.3.3.2 Government Initiatives in Europe

5 Pipeline Analysis

6 Competitive Landscape

  • 6.1 Key Developments and Strategies
    • 6.1.1 Collaborations and Partnerships
    • 6.1.2 Funding
    • 6.1.3 Product Launch and Upgradation
    • 6.1.4 Mergers and Acquisitions
    • 6.1.5 Others
  • 6.2 Business Model Analysis
    • 6.2.1 Subscription
    • 6.2.2 Software as a Service and Platform as a Service (SaaS and PaaS)
    • 6.2.3 Pay Per Use Model
  • 6.3 Competitive Benchmarking

7 Market Dynamics

  • 7.1 Market Drivers
    • 7.1.1 Increasing Drug Development Expenditure
    • 7.1.2 Facilitation of Polypharmacology
    • 7.1.3 Growing Number of Synergistic Activities
  • 7.2 Market Restraints
    • 7.2.1 Lack of Regulations
    • 7.2.2 Ethical Issues
  • 7.3 Market Opportunities
    • 7.3.1 Expansion of Business in Developing Economies such as India and Brazil
    • 7.3.2 Introduction of Solutions in Different Languages

8 Global AI-enabled Drug Discovery and Clinical Trials Market

  • 8.1 Assumptions and Limitations
  • 8.2 Key Findings and Opportunity Assessment
    • 8.2.1 Key Findings
    • 8.2.2 Opportunity Assessment

9 Global AI-enabled Drug Discovery and Clinical Trials Market (by Component)

  • 9.1 Overview
  • 9.2 Solutions
  • 9.3 Services

10 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)

  • 10.1 Overview
  • 10.2 Data Aggregation and Analysis
  • 10.3 Clinical Trials
  • 10.4 Drug Design
  • 10.5 Drug Characterization
  • 10.6 Biomarker Research

11 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Therapeutic Applications)

  • 11.1 Overview
  • 11.2 Oncology
  • 11.3 Cardiovascular Diseases
  • 11.4 Nervous System Diseases
  • 11.5 Respiratory Disorder
  • 11.6 Metabolic Diseases
  • 11.7 Immunologic Diseases
  • 11.8 Infectious Diseases
  • 11.9 Others

12 Global AI-Enabled Drug Discovery and Clinical Trials Market (by End User)

  • 12.1 Overview
  • 12.2 Biopharmaceutical Industry
  • 12.3 Contract Research Organizations (CROs)
  • 12.4 Academic Institutes and Research Centers

13 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region)

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 U.K.
    • 13.3.3 France
    • 13.3.4 Italy
    • 13.3.5 Spain
    • 13.3.6 Rest-of-Europe
  • 13.4 Asia-Pacific
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 South Korea
    • 13.4.4 Australia
    • 13.4.5 India
    • 13.4.6 Rest-of-Asia-Pacific
  • 13.5 Rest-of-the-World

14 Company Profiles

  • 14.1 Accutar Biotechnology Inc.
    • 14.1.1 Company Overview
    • 14.1.2 Role of Accutar Biotechnology Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.1.3 SWOT Analysis
  • 14.2 AiCure, LLC
    • 14.2.1 Company Overview
    • 14.2.2 Role of AiCure, LLC in Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.2.3 SWOT Analysis
  • 14.3 Ardigen
    • 14.3.1 Company Overview
    • 14.3.2 Role of Ardigen in Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.3.3 SWOT Analysis
  • 14.4 Atomwise, Inc.
    • 14.4.1 Company Overview
    • 14.4.2 Role of Atomwise, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.4.3 SWOT Analysis
  • 14.5 BenevolentAI
    • 14.5.1 Company Overview
    • 14.5.2 Role of BenevolentAI in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.5.3 SWOT Analysis
  • 14.6 Berg LLC
    • 14.6.1 Company Overview
    • 14.6.2 Role of Berg LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.6.3 SWOT Analysis
  • 14.7 Berkeley Lights, Inc.
    • 14.7.1 Company Overview
    • 14.7.2 Role of Berkeley Lights, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.7.3 SWOT Analysis
  • 14.8 BioAge Labs, Inc.
    • 14.8.1 Company Overview
    • 14.8.2 Role of BioAge Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.8.3 SWOT Analysis
  • 14.9 Biovista Inc.
    • 14.9.1 Company Overview
    • 14.9.2 Role of Biovista Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.9.3 SWOT Analysis
  • 14.10 C4X Discovery Holdings Plc
    • 14.10.1 Company Overview
    • 14.10.2 Role of C4X Discovery Holdings Plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.10.3 Financials
    • 14.10.4 Key Insights About the Financial Health of the Company
    • 14.10.5 SWOT Analysis
  • 14.11 Clinithink Ltd
    • 14.11.1 Company Overview
    • 14.11.2 Role of Clinithink Ltd in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.11.3 SWOT Analysis
  • 14.12 Cloud Pharmaceuticals, Inc.
    • 14.12.1 Company Overview
    • 14.12.2 Role of Cloud Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.12.3 SWOT Analysis
  • 14.13 Cyclica, Inc.
    • 14.13.1 Company Overview
    • 14.13.2 Role of Cyclica, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.13.3 SWOT Analysis
  • 14.14 CytoReason
    • 14.14.1 Company Overview
    • 14.14.2 Role of CytoReason in Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.14.3 SWOT Analysis
  • 14.15 Symphony Innovation, LLC
    • 14.15.1 Company Overview
    • 14.15.2 Role of Symphony Innovation, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.15.3 SWOT Analysis

Company Snapshots

  • 14.16 Deep Genomics Inc.
    • 14.16.1 Company Overview
    • 14.16.2 Role of Deep Genomics Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.17 DeepThink Health Inc.
    • 14.17.1 Company Overview
    • 14.17.2 Role of DeepThink Health Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.18 Envisagenics, Inc.
    • 14.18.1 Company Overview
    • 14.18.2 Role of Envisagenics, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.19 Exscientia Limited
    • 14.19.1 Company Overview
    • 14.19.2 Role of Exscientia Limited in Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.20 e-therapeutics plc
    • 14.20.1 Company Overview
    • 14.20.2 Role of e-therapeutics plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
    • 14.20.3 Financials
  • 14.21 GNS Healthcare
    • 14.21.1 Company Overview
    • 14.21.2 Role of GNS Healthcare in Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.22 Insilico Medicine
    • 14.22.1 Company Overview
    • 14.22.2 Role of Insilico Medicine in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.23 Lantern Pharma Inc.
    • 14.23.1 Company Overview
    • 14.23.2 Role of Lantern Pharma Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.24 Medable, Inc.
    • 14.24.1 Company Overview
    • 14.24.2 Role of Medable, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.25 Mind the Byte
    • 14.25.1 Company Overview
    • 14.25.2 Role of Mind the Byte in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.26 NuMedii, Inc
    • 14.26.1 Company Overview
    • 14.26.2 Role of NuMedii, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.27 Nuritas, Ltd.
    • 14.27.1 Company Overview
    • 14.27.2 Role of Nuritas, Ltd. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.28 Owkin, Inc.
    • 14.28.1 Company Overview
    • 14.28.2 Role of Owkin, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.29 Recursion Pharmaceuticals, Inc.
    • 14.29.1 Company Overview
    • 14.29.2 Role of Recursion Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.30 Schrodinger, LLC
    • 14.30.1 Company Overview
    • 14.30.2 Role of Schrodinger, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.31 TARA Biosystems, Inc.
    • 14.31.1 Company Overview
    • 14.31.2 Role of TARA Biosystems, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.32 twoXAR, Incorporated
    • 14.32.1 Company Overview
    • 14.32.2 Role of twoXAR, Incorporated in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.33 Verge Analytics, Inc.
    • 14.33.1 Company Overview
    • 14.33.2 Role of Verge Analytics, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.34 Winterlight Labs Inc.
    • 14.34.1 Company Overview
    • 14.34.2 Role of Winterlight Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.35 WuXi Nextcode Genomics
    • 14.35.1 Company Overview
    • 14.35.2 Role of WuXi Nextcode Genomics in Global AI-Enabled Drug Discovery and Clinical Trials Market
  • 14.36 XtalPi Inc.
    • 14.36.1 Company Overview
    • 14.36.2 Role of XtalPi Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market

List of Tables

  • Table 4.1: AI Incorporation by Healthcare Companies
  • Table 4.2: Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in North America
  • Table 4.3: Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
  • Table 4.4: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in North America
  • Table 4.5: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
  • Table 5.1: AI-Enabled Drugs Pipeline
  • Table 6.1: Competitive Benchmarking: Global AI-Enabled Drug Discovery and Clinical Trials Market
  • Table 10.1: Solution Providers: Drug Characterization
  • Table 13.1: Rest-of-the-World: Country-Wise Analysis, 2019-2030

List of Figures

  • Figure 1: Global AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 2: Impact Analysis
  • Figure 3: Share of Different Strategies
  • Figure 4: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Component 2018 vs. 2030 ($Million)
  • Figure 5: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Application, 2018 vs. 2030 ($Million)
  • Figure 6: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Therapeutic Application, 2018 vs. 2030 ($Million)
  • Figure 7: Global AI-Enabled Drug Discovery and Clinical Trials Market, by End User, 2018 vs. 2030 ($Million)
  • Figure 8: Global AI-Enabled Drug Discovery and Clinical Trials Market Snapshot
  • Figure 2.1: Global AI-Enabled Drug Discovery and Clinical Trials Market Segmentation
  • Figure 3.1: Global AI-Enabled Drug Discovery and Clinical Trials Market Methodology
  • Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Value Analysis: Drug Discovery
  • Figure 4.2: Stages of Clinical Trials
  • Figure 6.1: Share of Key Developments and Strategies, 2016-2019
  • Figure 6.2: Collaborations and Partnerships Share (by Company), 2016-2019
  • Figure 6.3: Funding Activity Share (by Company), 2016-2019
  • Figure 6.4: Product Launches (by Company), 2016-2019
  • Figure 6.5: Mergers and Acquisitions (by Company), 2016-2019
  • Figure 6.6: Other Activities (by Share), 2016-2019
  • Figure 7.1: Rising Drug Development Expenditure ($Billion), 1970s-2010s
  • Figure 7.2: Pharmaceutical vs. Government R&D Expenditure, 2014
  • Figure 9.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Component)
  • Figure 9.2: AI-Enabled Solutions for Drug Discovery and Clinical Trials: Usage Areas
  • Figure 9.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Solutions), 2018-2030
  • Figure 9.4: Global AI-Enabled Drug Discovery and Clinical Trials Market (Services), 2018-2030
  • Figure 10.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)
  • Figure 10.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (Data Aggregation and Analysis), 2018-2030
  • Figure 10.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Clinical Trials), 2018-2030
  • Figure 10.4: Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Design), 2018-2030
  • Figure 10.5: Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Characterization), 2018-2030
  • Figure 10.6: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biomarker Research), 2018-2030
  • Figure 11.1: AI Usage: Therapeutic Sections
  • Figure 11.2: AI-Enabled Oncology Clinical Trials (by Country)
  • Figure 11.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Oncology), 2018-2030
  • Figure 11.4: AI-Enabled Cardiovascular Diseases Clinical Trials (by Country)
  • Figure 11.5: Global AI-Enabled Drug Discovery and Clinical Trials Market (Cardiovascular Diseases), 2018-2030
  • Figure 11.6: AI-Enabled Nervous System Diseases Clinical Trials (by Country)
  • Figure 11.7: Global AI-Enabled Drug Discovery and Clinical Trials Market (Nervous System Diseases), 2018-2030
  • Figure 11.8: AI-Enabled Respiratory Disorders Clinical Trials (by Country)
  • Figure 11.9: Global AI-Enabled Drug Discovery and Clinical Trials Market (Respiratory Disorder), 2018-2030
  • Figure 11.10: AI-Enabled Metabolic Diseases Clinical Trials (by Country)
  • Figure 11.11: Global AI-Enabled Drug Discovery and Clinical Trials Market (Metabolic Diseases), 2018-2030
  • Figure 11.12: AI-Enabled Immunologic Diseases Clinical Trials (by Country)
  • Figure 11.13: Global AI-Enabled Drug Discovery and Clinical Trials Market (Immunologic Diseases), 2018-2030
  • Figure 11.14: Global AI-Enabled Drug Discovery and Clinical Trials Market (Infectious Diseases), 2018-2030
  • Figure 11.15: Global AI-Enabled Drug Discovery and Clinical Trials Market (Others), 2018-2030
  • Figure 12.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biopharmaceutical Industry), 2018-2030
  • Figure 12.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (CROs), 2018-2030
  • Figure 12.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Academic Institutes and Research Centers), 2018-2030
  • Figure 13.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region)
  • Figure 13.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region) 2018 vs. 2030
  • Figure 13.3: North America AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.4: North America: Market Dynamics
  • Figure 13.5: North America AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs. 2030
  • Figure 13.6: U.S. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.7: Canada AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.8: Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.9: Europe: Market Dynamics
  • Figure 13.10: Europe AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018-2030
  • Figure 13.11: Germany AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.12: U.K. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.13: France AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.14: Italy AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.15: Spain AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.16: Rest-of-Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.17: Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.18: Asia-Pacific: Market Dynamics
  • Figure 13.19: Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs 2030
  • Figure 13.20: China AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.21: Japan AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.22: South Korea AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.23: Australia AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.24: India AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.25: Rest-of-Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 13.26: Rest-of-the-World AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
  • Figure 14.1: Accutar Biotechnology Inc.: Product Offerings
  • Figure 14.2: Accutar Biotechnology Inc.: SWOT Analysis
  • Figure 14.3: AiCure, LLC: Product Offerings
  • Figure 14.4: AiCure, LLC: SWOT Analysis
  • Figure 14.5: Ardigen: Product Offerings
  • Figure 14.6: Ardigen: SWOT Analysis
  • Figure 14.7: Atomwise, Inc.: Product Offerings
  • Figure 14.8: Atomwise, Inc.: SWOT Analysis
  • Figure 14.9: BenevolentAI: Product Offerings
  • Figure 14.10: BenevolentAI.: SWOT Analysis
  • Figure 14.11: Berg LLC: Product Offerings
  • Figure 14.12: Berg LLC: SWOT Analysis
  • Figure 14.13: Berkeley Lights, Inc.: Product Offerings
  • Figure 14.14: Berkeley Lights, Inc.: SWOT Analysis
  • Figure 14.15: BioAge Labs, Inc.: Product Offerings
  • Figure 14.16: BioAge Labs, Inc.: SWOT Analysis
  • Figure 14.17: Biovista Inc.: Product Offerings
  • Figure 14.18: Biovista Inc.: SWOT Analysis
  • Figure 14.19: C4X Discovery Holdings Plc: Product Offerings
  • Figure 14.20: C4X Discovery Holdings Plc: Overall Financials (2016-2018)
  • Figure 14.21: C4X Discovery Holdings Plc: R&D Expenditure (2016-2018)
  • Figure 14.22: C4X Discovery Holdings Plc.: SWOT Analysis
  • Figure 14.23: Clinithink Ltd: Product Offerings
  • Figure 14.24: Clinithink Ltd: SWOT Analysis
  • Figure 14.25: Cloud Pharmaceuticals: Product Offerings
  • Figure 14.26: Cloud Pharmaceuticals, Inc.: SWOT Analysis
  • Figure 14.27: Cyclica, Inc.: Product Offerings
  • Figure 14.28: Cyclica, Inc.: SWOT Analysis
  • Figure 14.29: CytoReason.: Product Offerings
  • Figure 14.30: CytoReason: SWOT Analysis
  • Figure 14.31: Concerto HealthAI: Product Offerings
  • Figure 14.32: Concerto HealthAI: SWOT Analysis
  • Figure 14.33: e-therapeutics plc: Overall Financials (2016-2018)
  • Figure 14.34: e-therapeutics plc: R&D Expenditure (2016-2018)